Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (271-280 of 320) with videos related to

Pageof 32
Sort By:
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Breast Cancer Research and Treatment|April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patientsE S Bergen, C Tichy, A S Berghoff, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.
British Journal of Cancer|September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancerW Schippinger, H Samonigg, R Schaberl-Moser, et al.
British Journal of Cancer|September 30, 2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueA Michlmayr, T Bachleitner-Hofmann, S Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancerM Schmidt, D Rüttinger, M Sebastian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2005
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialM Karthaus, A Kretzschmar, H Kröning, et al.
Clinical & Experimental Metastasis|August 26, 2015
Activity of T-DM1 in Her2-positive breast cancer brain metastasesRupert Bartsch, Anna S Berghoff, Ursula Vogl, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2001
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trialM Schmidinger, A C Budinsky, C Wenzel, et al.
Pageof 32

Showing results (271-280 of 320) with videos related to

Sort By:
Pageof 32
BMC Cancer|October 20, 2009
Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancerRupert Bartsch, Catharina De Vries, Ursula Pluschnig, et al.
Breast Cancer Research and Treatment|April 25, 2016
Prognostic impact of breast cancer subtypes in elderly patientsE S Bergen, C Tichy, A S Berghoff, et al.
Journal of Cancer Research and Clinical Oncology|May 3, 2005
The efficacy of trastuzumab in Her-2/neu-overexpressing metastatic breast cancer is independent of p53 statusWolfgang J Köstler, Thomas Brodowicz, Gernot Hudelist, et al.
British Journal of Cancer|September 27, 2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancerW Schippinger, H Samonigg, R Schaberl-Moser, et al.
British Journal of Cancer|September 30, 2010
Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive valueA Michlmayr, T Bachleitner-Hofmann, S Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2024
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER TrialAlexios Matikas, Volker Möbus, Richard Greil, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancerM Schmidt, D Rüttinger, M Sebastian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 2005
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trialM Karthaus, A Kretzschmar, H Kröning, et al.
Clinical & Experimental Metastasis|August 26, 2015
Activity of T-DM1 in Her2-positive breast cancer brain metastasesRupert Bartsch, Anna S Berghoff, Ursula Vogl, et al.
Cancer Chemotherapy and Pharmacology|February 28, 2001
Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trialM Schmidinger, A C Budinsky, C Wenzel, et al.
Pageof 32